-
公开(公告)号：US10980859B2
公开(公告)日：2021-04-20
申请号：US15058456
申请日：2016-03-02
Applicant: Hangzhou Converd Co., Ltd.
Inventor： Fang Hu , Ronghua Zhao , Siyi Chen , Bo Wu , Huiqun Xia , Yanjun Zheng
IPC: A61K38/19 , A61K35/761 , A61K45/06 , A61K31/513 , A61K31/7068 , A61K31/704 , A61K33/24 , A61K31/475 , A61K35/768 , A61K38/48 , A61K35/763 , A61K35/74 , A61K38/55 , A61K35/766 , C07K16/28 , A61K39/395 , C07K16/30 , C12N7/00 , A61K39/00
Abstract: The invention provides an in vivo individualized systemic immunotherapeutic method and device. The method includes, in a non-sequential manner: (1) increasing release amount of tumor antigens at a tumor site; (2) at the tumor site, increasing level of proteins capable of adhering to and/or wrapping the tumor antigens; (3) at the tumor site, increasing level of dedicated antigen-presenting cells involved in immunity, and establishing, between the dedicated antigen-presenting cells and immune effector cells, a close connection capable of activating the immune effector cells; and (4) at the tumor site, increasing level and improving function of the immune effector cells. The steps (1)-(4) each reaches a maximum value at a respective time which overlaps with each other maximally, as well as at a respective site which overlaps with each other maximally. The invention combines oncolytic therapy and immunotherapy, in individualized systemic immunotherapy, and provides significantly improved therapeutic effect.
-
公开(公告)号：US11071737B2
公开(公告)日：2021-07-27
申请号：US16064464
申请日：2016-12-20
Inventor： Shuiping Shi , Qingyong Zhang , Ronghua Zhao , Huihong Chen , Lun Zeng , Daxin Ou , Yan Liu
Abstract: A pharmaceutical composition comprises an active component KX2-361 represented by formula 1 or a medicinal salt thereof and hydroxylpropoxyl-β-cyclodextrin. An inclusion compound is formed by KX2-361 or the medicinal salt thereof and hydroxylpropoxyl-β-cyclodextrin, and the solubility of the poorly-soluble drug KX2-361 is improved. The pharmaceutical composition can be prepared into an intravenous preparation and an oral preparation.
-
3.发明申请公开(公告)号：US20200289591A1
公开(公告)日：2020-09-17
申请号：US16650076
申请日：2018-06-28
Applicant: Hangzhou Converd Co., Ltd.
Inventor： Jin Fu , Ronghua Zhao , Rong Zhang , Tingting Wang , Lin Chen , Fang Hu
IPC: A61K35/768 , C12N7/00 , A61P35/00
Abstract: The invention provides an isolated recombinant oncolytic vaccinia virus, pharmaceutical compositions and uses thereof for drugs for treatment of tumors and/or cancers. The isolated recombinant oncolytic vaccinia virus is functionally deficient in the TK gene and the VGF gene, and the genome of the recombinant oncolytic vaccinia virus is integrated with an exogenous IL-21 gene, and wherein the IL-21 gene is capable of being expressed in tumor cells. The recombinant oncolytic vaccinia virus can selectively replicate in tumor cells, and can also fully exert the anti-tumor immune effect of the exogenous IL-21, such that the oncolytic killing effect of the oncolytic virus and the anti-tumor immune stimulation effect of IL-21 achieve a synergic effect.
-
Patent Agency Ranking
公开(公告)号：US11806374B2
公开(公告)日：2023-11-07
申请号：US16650863
申请日：2018-07-03
Applicant: HANGZHOU CONVERD CO., LTD.
Inventor： Jipo Sheng , Jin Fu , Ronghua Zhao , Yun Qin , Lin Chen , Sanmao Kang , Fang Hu
IPC: A61K39/23 , C12N15/79 , C07H21/04 , A61K35/761 , A61P35/00 , C12N7/00 , C12N15/113 , C12N15/63 , A61K48/00 , C12N15/64
CPC classification number: A61K35/761 , A61K48/005 , A61P35/00 , C12N7/00 , C12N15/113 , C12N15/1135 , C12N15/63 , C12N15/64 , C12N2310/531 , C12N2710/10332 , C12N2710/10343
Abstract: The present disclosure provides an isolated recombinant oncolytic adenovirus, a pharmaceutical composition, and uses thereof for drugs for treatment of tumors and/or cancers. The recombinant oncolytic adenovirus is a selectively replicating oncolytic adenovirus, and the genome of the recombinant oncolytic adenovirus is integrated with a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells. The replication capability of the virus in normal primary cells is much lower than the replication capability of the virus in tumor cells. Moreover, the expressed shPDL1 can significantly reduce the level of PDL1 protein highly expressed in tumor cells. Thus, the oncolytic killing effect of the oncolytic virus and the anti-tumor immunostimulatory effect of immune cells produce a synergistic effect.
-
5.发明授权公开(公告)号：US11357804B2
公开(公告)日：2022-06-14
申请号：US16478727
申请日：2018-01-24
Applicant: HANGZHOU CONVERD CO., LTD.
Inventor： Ronghua Zhao , Yanjun Zheng , Fang Hu
IPC: A61K35/761 , A61P37/02 , A61P35/00 , C12N7/00
Abstract: Provided is the use of selectively replicating oncolytic viruses in the preparation of immunostimulants for treatment of tumors and/or cancers, wherein the oncolytic viruses do not carry exogenous immunoregulatory genes.
-
公开(公告)号：US11446345B2
公开(公告)日：2022-09-20
申请号：US16474349
申请日：2018-01-03
Applicant: HANGZHOU CONVERD CO., LTD.
Inventor： Fang Hu , Lin Chen , Ronghua Zhao
IPC: A61K35/761 , A61P35/00 , A61K35/17 , A61K35/768 , A61K35/763 , A61K35/765 , A61K35/766 , A61K35/76
Abstract: The present disclosure provides therapeutic agents and uses thereof for drugs for treatment of tumors and/or cancers. The active ingredients of the therapeutic agents comprise an oncolytic virus that selectively replicate in tumor cells and comprise NK cells.
-
公开(公告)号：US11007141B2
公开(公告)日：2021-05-18
申请号：US16064466
申请日：2016-12-20
Inventor： Shuiping Shi , Qingyong Zhang , Ronghua Zhao , Huihong Chen , Lun Zeng , Daxin Ou , Yan Liu
Abstract: An oral preparation for treating cell proliferation diseases. The oral preparation comprises hydroxylpropoxyl-β-cyclodextrin and an active component. The active component is KX2-361 or a medicinal salt thereof, and KX2-361 is represented by formula 1. By mixing hydroxylpropoxyl-ydcyclodextrin with KX2-361 or the medicinal salt thereof, an inclusion complex is formed, the solubility of the poorly-soluble drug KX2-361 is greatly improved, and accordingly the drug is prepared into an oral preparation. The oral preparation has good stability, high safety, good absorbability, high bioavailability and economical cost.
-
公开(公告)号：US20160250292A1
公开(公告)日：2016-09-01
申请号：US15058456
申请日：2016-03-02
Applicant: Hangzhou Converd Co., Ltd.
Inventor： Fang Hu , Ronghua Zhao , Siyi Chen , Bo Wu , Huiqun Xia , Yanjun Zheng
IPC: A61K38/19 , C12N7/00 , A61K39/395 , C07K16/30 , A61K35/761 , C07K16/28
CPC classification number: A61K38/193 , A61K31/475 , A61K31/513 , A61K31/704 , A61K31/7068 , A61K33/24 , A61K35/74 , A61K35/761 , A61K35/763 , A61K35/766 , A61K35/768 , A61K38/191 , A61K38/4873 , A61K38/55 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2818 , C07K16/2827 , C07K16/30 , C07K2317/76 , C12N7/00 , C12N2710/10332 , Y02A50/466 , Y02A50/484 , A61K2300/00
Abstract: The invention provides an in vivo individualized systemic immunotherapeutic method and device. The method includes, in a non-sequential manner: (1) increasing release amount of tumor antigens at a tumor site; (2) at the tumor site, increasing level of proteins capable of adhering to and/or wrapping the tumor antigens; (3) at the tumor site, increasing level of dedicated antigen-presenting cells involved in immunity, and establishing, between the dedicated antigen-presenting cells and immune effector cells, a close connection capable of activating the immune effector cells; and (4) at the tumor site, increasing level and improving function of the immune effector cells. The steps (1)-(4) each reaches a maximum value at a respective time which overlaps with each other maximally, as well as at a respective site which overlaps with each other maximally. The invention combines oncolytic therapy and immunotherapy, in individualized systemic immunotherapy, and provides significantly improved therapeutic effect.
Abstract translation: 本发明提供一种体内个体化的全身免疫治疗方法和装置。 该方法以非顺序方式包括：（1）增加肿瘤部位肿瘤抗原的释放量; （2）在肿瘤部位，增加能够粘附和/或包裹肿瘤抗原的蛋白质水平; （3）在肿瘤部位增加参与免疫的专用抗原呈递细胞的水平，并且在专用抗原呈递细胞和免疫效应细胞之间建立能够激活免疫效应细胞的紧密连接; 和（4）在肿瘤部位，增加免疫效应细胞的水平和改善功能。 步骤（1） - （4）各自在最大相互重叠的相应时间以及最大重叠的相应位置处达到最大值。 本发明结合了溶瘤治疗和免疫治疗，在个体化的全身免疫治疗中，提供了显着改善的治疗效果。
-
-
-
-
-
-
-
Search Results
8
records
(took 0.016 seconds)
